---
figid: PMC5948714__12885_2018_4441_Fig1_HTML
figlink: /pmc/articles/PMC5948714/figure/Fig1/
number: F1
caption: Restoring T-cell activation through the use of checkpoint inhibitors. a Naïve
  T cells become activated following their recognition of peptides presented in the
  context of MHC molecules expressed on the surface of antigen presenting cells, such
  as dendritic cells, along with engagement of costimulatory molecules (B7) with CD28
  and this activation results in upregulation of cytotoxic T-lymphocyte antigen 4
  (CTLA-4). The CTLA-4 receptor on T lymphocytes is a negative regulator of T cell
  activation that outcompetes CD28 for binding to B7 on antigen presenting cells in
  order to block T cell responses. Another inhibitory pathway uses the programmed
  cell death 1 (PD-1) receptor. CTLA-4 and PD-1 modulate different aspects of the
  T cell response. CTLA-4 is rapidly induced in T cells, following activation via
  MHC/TCR and B7/CD28 mediated signaling. In contrast, the major role of the PD1 pathway
  is to regulate inflammatory responses in tissues by effector T cells recognizing
  antigen in peripheral tissues. b Cancers can express the ligands for these checkpoint
  molecules, thus blocking T cell responses. Thus, the use of checkpoint inhibitors
  allow T cells to maintain their effector functions via the secretion of cytokines
  that recruit other immune cells to participate in the antitumor response and through
  their cytolytic capabilities. Numerous checkpoint inhibitors are currently being
  used in the clinic. CTLA-4, cytotoxic T-lymphocyte antigen; PD-1, programmed death
  1; PD-L1, programmed death ligand 1; APC, antigen presenting cell; MHC, major histocompatibility
  complex; TCR, T cell receptor
pmcid: PMC5948714
papertitle: Mechanisms of immune evasion in breast cancer.
reftext: Joshua P. Bates, et al. BMC Cancer. 2018;18:556.
pmc_ranked_result_index: '58386'
pathway_score: 0.9658798
filename: 12885_2018_4441_Fig1_HTML.jpg
figtitle: Restoring T-cell activation through the use of checkpoint inhibitors
year: '2018'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5948714__12885_2018_4441_Fig1_HTML.html
  '@type': Dataset
  description: Restoring T-cell activation through the use of checkpoint inhibitors.
    a Naïve T cells become activated following their recognition of peptides presented
    in the context of MHC molecules expressed on the surface of antigen presenting
    cells, such as dendritic cells, along with engagement of costimulatory molecules
    (B7) with CD28 and this activation results in upregulation of cytotoxic T-lymphocyte
    antigen 4 (CTLA-4). The CTLA-4 receptor on T lymphocytes is a negative regulator
    of T cell activation that outcompetes CD28 for binding to B7 on antigen presenting
    cells in order to block T cell responses. Another inhibitory pathway uses the
    programmed cell death 1 (PD-1) receptor. CTLA-4 and PD-1 modulate different aspects
    of the T cell response. CTLA-4 is rapidly induced in T cells, following activation
    via MHC/TCR and B7/CD28 mediated signaling. In contrast, the major role of the
    PD1 pathway is to regulate inflammatory responses in tissues by effector T cells
    recognizing antigen in peripheral tissues. b Cancers can express the ligands for
    these checkpoint molecules, thus blocking T cell responses. Thus, the use of checkpoint
    inhibitors allow T cells to maintain their effector functions via the secretion
    of cytokines that recruit other immune cells to participate in the antitumor response
    and through their cytolytic capabilities. Numerous checkpoint inhibitors are currently
    being used in the clinic. CTLA-4, cytotoxic T-lymphocyte antigen; PD-1, programmed
    death 1; PD-L1, programmed death ligand 1; APC, antigen presenting cell; MHC,
    major histocompatibility complex; TCR, T cell receptor
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD28
  - CTLA4
  - PDCD1
  - CD274
  - TRA
  - TRB
  - TRD
  - TRG
  - TCR
genes:
- word: CD28
  symbol: CD28
  source: hgnc_symbol
  hgnc_symbol: CD28
  entrez: '940'
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PDL-1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
chemicals:
- word: TCR
  source: MESH
  identifier: D017260
diseases: []
figid_alias: PMC5948714__F1
redirect_from: /figures/PMC5948714__F1
figtype: Figure
---
